autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
Term · Oncology and biomedicine · MLC-T-ONC-011540
A preparation of genetically modified autologous central memory (Tcm) enriched T cells transduced with a replication incompetent lentiviral vector expressing a chimeric antigen receptor (CAR), containing a CD28 signaling domain fused to both CD3 zeta, which targets the CD19 antigen, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells are directed to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity response. The costimulatory signaling domain enhances proliferation of T cells and antitumor activity.
| Identifier | MLC-T-ONC-011540 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | CD19R:CD28:lentiviral/EGFRt+ T cells; autologous CD19R:CD28:lentiviral/EGFRt+ T cells |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011540",
"term": "autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells",
"field": "Oncology and biomedicine",
"definition": "A preparation of genetically modified autologous central memory (Tcm) enriched T cells transduced with a replication incompetent lentiviral vector expressing a chimeric antigen receptor (CAR), containing a CD28 signaling domain fused to both CD3 zeta, which targets the CD19 antigen, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells are directed to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity response. The costimulatory signaling domain enhances proliferation of T cells and antitumor activity.",
"synonyms": [
"CD19R:CD28:lentiviral/EGFRt+ T cells",
"autologous CD19R:CD28:lentiviral/EGFRt+ T cells"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/autologous-cd19car-cd28-cd3zeta-egfrt-expressing-tcm-enriched-t-cells/"
}
Record 2,874 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.